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Abstract 
 
The present study was undertaken to evaluate the antinociceptive interaction between tramadol and xylazine. The 
antinociceptive effect of intraperitoneal (I.P) administration of the drug alone or in combination was evaluated using the mouse 
hot-plate test. Administration of tramadol in fixed dose (20mg\kg) I.P with different doses of xylazine (0, 2, 4, 8) mg\kg I.P 
significantly referred synergism of the antinociceptive effect of tramadol depending on the dose of xylazine. There was an 
increased the antinociceptive maximum possible effect (%MPE) from (27.08%) to (85.4%). The effective dose that produce 
50% antinociceptive (ED50) were evaluated for each drug alone or in combination. The present study found that the 
administration of tramadol and xylazine markedly reduced the median effective dose (ED50) of both drugs for antinociceptive 
effect in mice. The result of this study demonstrated that there was synergism (super-additive) interaction between tramadol 
and xylazine.  
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رزأت ةيلاعفلا    نكسملا ة   ل لودامارتل   افلا لبقتم عم - ٢ يلانيردلاا    نيزليازلا   نارئفلا يف   
  
ةقاط نمحرلا دبع ةداغ  
 
ةيساسلأا مولعلا مسق ،   نانسلأا بط ةيلك ،   ةعماج لصوملا  قارعلا ،لصوملا ،   
ةصلاخلا   
  
 فدھت  ةساردلا  ىلا يقت ي  م ريثأتلا   نكسملا نيزلايازلاو لودامارتلا نيب يئاودلا لخادتلل   . ةساردلا ءارجا مت ثيح نع     قيرط  لعفلا سايق
تلا نم لكل نكسملا ر لوداما نيزلايازلاو  بلخلا يف ةاطعملا  نارئفلا يف ةنخاسلا ةحيفصلا رابتخا مادختساب  .   ىدا   ا ءاطع  ةعرجب لودامارتلا 
 ةتباث ) ٢٠   مغلم  / مغك ( بلخلاب  ، عم  نم ةفلتخم تاعرج     نيزلايازلا ) ٠  ، ٢  ، ٤  ، ٨ مغلم  / مغك  (  ،بلخلاب لودامارتلل نكسملا لعفلا ةيوقت ىلا  
ةعرج ةدايز ىلع دامتعلاابو ايونعم نيزلايازلا  .   كانھ نا ظحول دقو   يف ةدايز  ةيوئملا ةبسنلا  نيكستلل   ) MPE % (   نم   ) ٢٧,٠٨  (% ىلا  
) ٨٥,٤  .(% ةيطسولا ةنكسملا ةعرجلا س ايق متو امك   ) مجلا   ٥٠ (   ءاطعا دنع لك  طعا دنع وا هدحول ءاود   ا اعم امھئ ،    تلصوت ثيح  ةساردلا
نا ىلا  عم لودامارتلا ءاطعا   نيزلايازلا ضافخنا لجس دق يف اظوحلم ا سملا ةعرجلا   ةيطسولا ةنك امھلاك نيئاودلل نارئفلا يف  .    ترھظا دقل
 نيب لخادتلا نا جئاتنلا  نيزلايازلاو لودامارتلا وھ   يرزأت .     
  
 
Introduction 
 
Xylazine and tramadol are both widely used to treat 
moderate and severe pain (1,2). Xylazine is an α2 
adrenergic receptor agonist that produces sedation, 
analgesia, and muscle relaxation with administrated 
parentrally to animals (3). The mechanism of action of 
xylazine to produce antinociceptive is effected by its 
activation presynaptic α2 receptor, thus lead to decrease the 
amount of noradrenaline and dopamine, therefore lead to 
depression of the brain (4,5). 
Tramadol is a centrally acting synthetic analgesic drug 
with both opioid and non opioid properties (6,7). The 
antinociceptive effect of tramadol result from dual 
mechanism of action, first; the affinity of tramadol for µ-
opioid receptor and the second; tramadol has inhibition of Iraqi Journal of Veterinary Sciences, Vol. 26, No. 2, 2012 (109-113)  
 
  110
the presynaptic reuptake of norepinephrine and serotonin. 
The inhibitory effect contributing to analgesic effect of 
tramadol by inhibiting pain transmission in the central 
nervous system (7,8). 
In case of different analgesics combination, the method 
of achieving one or more therapeutic aim will be managed. 
This will result in facilitate the compliance of patient, 
prescription will be more simplified, the efficacy will have 
more improved without increasing side effects of analgesic 
drugs combination (9). 
The α2-agonists have an significant hypnotic interaction 
with others anesthetics and an analgesic interaction with 
opioid (10). However, the analgesic interaction of xylazine–
tramadol have not been evaluated. Therefore the present 
study was to evaluate the effect of selective α2 adrenoceptor 
agonist xylazine on tramadol antinociceptive effect and 
evaluation the type of interaction of these two drugs, using 
a hot-plate test in mice. Hot-plate test is a pain assessment 
method used in experimental animal to measurement the 
pain by using a thermal stimulus.  
  
Materials and methods 
 
Animal 
Fifty five male albino mice weighing 25-30 g were 
used. The animals were housed at 22±2°C on a 12 h 
light\dark cycle and fed with standard diet and water ad 
libitum. The mice were obtained from animal care in 
Collage of Dentistry, University of Mosul, Iraq.  
 
Measurement of analgesic activity 
The median analgesic dose of tramadol and xylazine 
either individually or in combination were studied on 
mouse by Hot-plate test: Mice were placed on a hot-plate 
maintained at 55±1C
0. The response latency (analgesic 
activity) was evaluated on the basis of either fore or hind 
paw lick or jump reaction, following contact with the hot-
plate (11).The ED50 for 2 drugs were determine according 
to Dixon table (12). 
 
Evaluation the effect of different doses of xylazine on 
tramadol analgesia  
The animals were divided randomly into 5 groups, each 
group consisted of six animals. The mice were injected with 
fixed dose of tramadol hydrochloride 5% (Mepha Ltd 
Aesh-Basel Swit-sland) at 20mg\kg IP and different doses 
of xylazine 2% (Holland, Castenray, Interchemra) (0,2,4,8 
mg\kg IP). Xylazine in different doses were injected after 
15 min of tramadol administration. The analgesic activity 
was evaluated according to the above (11) and the 
percentage of antinociceptive maximal possible effect 
(MPE) was calculated according to the formula (13): 
 
%MPE= Test latency - predrug latency/cut off time - 
predrug latency × 100. 
 
MPE: Percentage of antinociception maximal possible 
effect. Test latency : sec after drug treatment. 
Predrug latency : second before drug treatment at zero time. 
Cut off time : 30 second. 
 
Antinociceptive interaction between tramadol and 
xylazine  
In the present study determined the median effective 
dose (ED50) of tramadol and xylazine each one alone by up 
and down method for antinociceptive activity (11). The 
interaction between 2 drugs were evaluated simultaneous 
administration of fixed ED50 ratio of tramadol with 
different ED50 ratio of xylazine, and performing an 
isobolographic analysis for the different combination as 
described by Tallarida et al (14).  
In the present study fixed ratio were selected by 
combining the ED50 of tramadol and xylazine (1:1, 1:0.5) 
respectively. The ED50 point of tramadol is represent X 
axis while ED50 of xylazine is represent in Y axis. A 
diagonal line is drawn to join the isoeffective dose on the 
axis. Doses of drug combination producing the same effect 
are then plotted. Point falling on the diagonal line represent 
zero interaction (additively),while those located above and 
below are antagonistic and synergistic, respectively (15).  
The interaction index was calculated using the 
following equation: (Y=a\A+b\B) 
Where A and B are individual ED50 of tramadol and 
xylazine respectively and (a,b) are the combination doses 
that produce the same effect. An interaction index, if Y<1, 
it is supra-additive (Synergy); and if Y> 1 its sub-additive 
(antagonism).  
  
Statistical analysis 
The data were expressed as mean±SD, difference 
between three experimental groups were statistically 
analyzed by one way analysis of variance (ANOVA) 
followed by the least significant difference test. The level 
of significance was at P<0.05. (16) 
 
Results 
 
Antinociceptive effect of different doses of xylazine with 
tramadol in hot plate test 
Systemic I.P administration of different doses of 
xylazine and tramadol produce a dose dependent 
antinociceptive effect in mice tested by hot-plate test assay. 
The latency time reaction was significantly increased 
represented by increasing the latency time from (12.5) sec 
in group treated with tramadol alone in comparison with 
others treated group with tramadol and xylazine together at Iraqi Journal of Veterinary Sciences, Vol. 26, No. 2, 2012 (109-113)  
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(20+4 mg\kg IP) and (20+4 mg\kg IP) to (19.75) (26.5)sec 
respectively. The increased in latency time proportional 
with increased the dose of xylazine (table 1). The 
percentage of pain inhibition, maximal possible effect 
(MPE), was significantly increased from (39.58 %) in low 
dose of xylazine to (85.4%) in high dose when fixed the 
dose of tramadol table (1) at P< 0.05.  
 
Table 1: Antinociceptive effects of tramadol (fixed dose) 
alone and in combination with xylazine in the hot-plate test 
in mice. 
 
 Treatment groups   Latency time 
(seconds) 
% Pain 
inhibition 
(%MPE) 
Tramadol 20mg\kg IP + 
normal saline IP  12.5±3.1 27.08 
Tramadol 20mg\kg IP+ 
Xylazine 2mg\kg IP  15.5±4.4 39.58  * 
Tramadol 20mg\kg IP+ 
Xylazine 4mg\kg IP  19.7±3.5 *  57.08 * a 
Tramadol 20mg\kg IP+ 
Xylazine 8mg\kg IP  26.5±6.2 *a b  85.40 * a b 
Value are mean + SE 6 mice /group, * Significantly 
different from the control group at P<0.05, a. Significantly 
different from tramadol 20mg\kg + xylazine 2mg\kg group 
at P<0.05, b. Significantly different from tramadol 20 
mg\kg + xylazine 4mg\kg  group at P<0.05.  
 
Interaction of tramadol and α2 adrenoreceptor: 
The ED50 for tramadol and xylazine antinociceptive 
determined were 19.4 and 3.2 mg\kg IP respectively Table 
(2,3). However when coadministration Tramadol and 
xylazine reduced the ED50 for tramadol produce 
antinociceptive in the mice to (11.18) and (7.86) mg\kg IP 
after used in ratio (1:0.5) and (1:1) respectively Table (4, 
5). The antinociceptive activity induced by 
coadministration of fixed ratio ED50 fraction of tramadol 
and xylazine was examined by isobolographic analysis after 
I.P administration. The ED50 values for the combination 
were shown in (table 6) and the type of interaction were 
shown in (figure 1and 2). 
 
Table 2: Determination of median effective doses (ED50) 
of tramadol for antinociceptive effect in mice.  
 
Variable   Result 
ED50 19.4  mg\kg  IP 
Range of the doses used   18-20 mg\kg IP 
Initial dose   20 mg\kg IP 
Last dose   20 mg\kg IP 
Number of mice used  5 (XOOXX) 
Increase or decrease in the dose   2 mg\kg IP 
The isobolographic analysis for combination tramadol 
and xylazine showed a synergistic antinociceptive 
interaction between two drugs, and the Y calculated from 
equation is appear lower than 1(Y<1), thus this indicated 
that interaction is synergy. Table (6 ). 
 
Table 3: Determination of median effective doses (ED50) 
of for xylazine antinociceptive effect in mice. 
 
Variable   Result 
ED50 3.2  mg\kg  IP 
Range of the doses used   1 - 4 mg\kg IP 
Initial dose   1 mg\kg IP 
Last dose   4 mg\kg IP 
Number of mice used  6 (OOXOOX) 
Increase or decrease in the dose   1 mg\kg IP 
 
Table 4: Determination of median effective doses (ED50) 
of interaction tramadol and xylazine in ratio (1:0.5). 
 
Variable   Result for 
tramadol 
Result for 
xylazine 
ED50  11.18  
mg\kg IP 
0.23  
mg\kg IP 
Range of the doses used   10.4-19.4  
mg\kg IP 
0.1- 1.6  
mg\kg IP 
Initial dose   19.4  
mg\kg IP 
1.6  
mg\kg IP 
Last dose   13.4  
mg\kg IP 
0.6  
mg\kg IP 
Number of mice used  7 
(XXXOXOX) 
7 
(XXXOXOX) 
Increase or decrease in 
the dose  
3  
mg\kg IP 
0.5  
mg\kg IP 
 
Table 5: Determination median effective doses (ED50) of 
interaction tramadol and xylazine in ratio (1:1) 
 
Variable   Result for 
tramadol 
Result for 
xylazine 
ED50  7.86  
mg\kg IP 
1.28  
mg\kg IP 
Range of the doses used   7.4- 19.4  
mg\kg IP 
1.3 - 3.2  
mg\kg IP 
Initial dose   19.4  
mg\kg IP 
3.2  
mg\kg IP 
Last dose   7.4  
mg\kg IP 
1.2  
mg\kg IP 
Number of mice used  7 
(XXXOXXX) 
7 
(XXXOXXX) 
Increase or decrease in 
the dose  
3  
mg\kg IP 
0.5  
mg\kg IP 
 Iraqi Journal of Veterinary Sciences, Vol. 26, No. 2, 2012 (109-113)  
 
  112
Table 6: The ED50 values for the interaction of tramadol 
and xylazine in ration (1:0.5, 1:1). 
 
Parameters Gp1  Gp2  Gp3  Gp4 
Tramadol+ xylazine  T 
alone 
X 
alone  T: X  T:X 
Ratio -  -  1:0.5  1:1 
number on mice   5  6  7  7 
ED50 mg\kg   19.4  3.2  19.4:1.6  19.4:3.2 
ED50mixing mg\kg   -  -  11.18:0.23 7.86:1.28
Y(interaction index)   -  -  0.647  0.805 
 
 
 
 
Figure 1: Isobolographic representation of the interaction 
between tramadol and xylazine in a ratio 1: 0.5 fixed 
potency ratio at the 50% level of response (ED50). The 
interaction of tramadol with xylazine demonstrates synergy. 
 
 
  
Figure 2: Isobolographic representation of the interaction 
between tramadol and xylazine in a ratio 1: 1 fixed potency 
ratio at the 50% level of response (ED50). The interaction 
of tramadol with xylazine demonstrates synergy. 
 
Discussion 
 
Many reports have been published on analgesic 
combination such as Ketoprofen with acetaminophen, 
Tramadol with acetaminophen (17,18). It has also been 
demonstrated that the combination of drug acting on 
different receptor may produce super or sub additive 
interaction in antinociceptive effects (15). 
The results demonstrated that a synergism of the 
analgesic activity of opioid (tramadol) and α2 adrenergic 
agonist (xylazine). The synergism antinociception effect 
between tramadol and xylazine may be because tramadol 
has weak opioid agonist with antinociceptive effects 
through its action on µ-receptor or by inhibiting the 
neuronal reuptake of both noradrenaline and serotonin (7). 
Many study demonstrated that tramadol has the 
antinociceptive effect through acting on descending 
noradrenergic pathway and this play a role in analgesic 
properties of the non opioid, stimulating this pathway 
produces antinociceptive effect from the activation of the 
spinal  α2 adrenergic receptor by noradrenergic neuron 
(19,20). 
The α2 adrenoreceptor agonist xylazine is widely used 
in veterinary practice as a sedative, analgesic and muscle 
relaxant (20). The analgesic effect of xylazine is produced 
by centrally activation of presynaptic α-2 adrenoceptor, 
causing decrease in the release and turnover of 
noradrenaline and dopamine (4,5). Also, xylazine has other 
properties similar to that of opioid (2). Xylazine and other 
α2 agonist such as detomidine, and medetomidine were 
potential the analgesic properties of opioid (10,22). 
The alpha2- agonist can induce analgesia by acting at 
three different locations: in brain and brain stem, spinal 
cord and in peripheral tissues. Alpha2-adrenergic and 
opioidergic system have common effector mechanisms in 
locus coeruleus, probably through a common transduction 
mechanism, responding a supraspinal site of action (23). In 
the spinal cord, the analgesic action of alpha2- agonist is 
likely related to activation of descending medullospinal 
noradrenergic pathway or to the reduction of spinal 
sympathetic outflow at presynaptic ganglionic sites. There 
is also significant interaction between opioid and alpha2- 
agonists at the spinal cord level which contribute to the 
usefulness of this class of agent in the clinical setting (24). 
The current results indicate that xylazine can synergistic 
the analgesic properties of opioid. The synergistic activities 
of α2 adrenoreceptor agonist could be measurement both in 
reduction the amount of opioid needed to reach particular 
level of analgesia with a fixed dose of the opioid. This 
result agreement with previous study suggested that the 
administration of fentanyl like opioid potentiate the 
analgesic properties of α2 adrenoreceptor agonist (10). 
A synergistic interaction between α2 adrenoreceptor 
agonist and opioid has been demonstrated (25). The 
antinociceptive effect of spinal α2 adrenoreceptor agonist 
seem to be a direct action on dorsal horn neuron on 
supraspinal and spinal sites and activate descending 
inhibitory system (26). Activation of α1 and α2 Iraqi Journal of Veterinary Sciences, Vol. 26, No. 2, 2012 (109-113)  
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adrenoreceptor either located pre and\or post synaptic level 
are involved in the control of spinal antinociception (27). 
Drugs that act at α2 adrenoreceptor and opioid receptor 
as agonist inhibit pain transmission in the spinal cord when 
administration together, agonists activating these receptor 
interact in synergistic manner (22). Previous study 
suggested that the administration of synergistic receptor 
pair α2 adrenoreceptor and opioid receptor on nociceptive 
fibers can produce analgesic synergy, this may be a result 
of interaction between neuronal G -protein coupled 
receptors (28). α2 adrenoreceptor coupled to sensitive 
inhibitory G –protein that causing inhibition of adenylase 
cyclase activity which result in decrease formation of 
CAMP, is an important consequence of α2-adrenoceptor 
activation (29). 
 
Conclusion 
 
The administration tramadol with α2 adrenoreceptor 
xylazine demonstrated synergy in antinociceptive effect, 
because two drugs have the same pathway inhibited the 
pain transmission through acting on α2 adrenoreceptor and 
opioid receptor.  
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